MA26817A1 - Formulations de lipides solides - Google Patents

Formulations de lipides solides

Info

Publication number
MA26817A1
MA26817A1 MA26544A MA26544A MA26817A1 MA 26817 A1 MA26817 A1 MA 26817A1 MA 26544 A MA26544 A MA 26544A MA 26544 A MA26544 A MA 26544A MA 26817 A1 MA26817 A1 MA 26817A1
Authority
MA
Morocco
Prior art keywords
solid lipid
lipid formulations
formulations
solid
lipid
Prior art date
Application number
MA26544A
Other languages
English (en)
Inventor
Smidt Passchier Christiaan De
Hans Lengsfeld
Marcel Schmid
Hans Steffen
Joseph Tardio
David Macfarland Small
Paul Hadvary
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26817A1 publication Critical patent/MA26817A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
MA26544A 1999-09-13 2002-03-11 Formulations de lipides solides MA26817A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118179 1999-09-13

Publications (1)

Publication Number Publication Date
MA26817A1 true MA26817A1 (fr) 2004-12-20

Family

ID=8238989

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26544A MA26817A1 (fr) 1999-09-13 2002-03-11 Formulations de lipides solides

Country Status (36)

Country Link
US (1) US6703369B1 (fr)
EP (1) EP1216048B1 (fr)
JP (1) JP4217017B2 (fr)
KR (1) KR100523879B1 (fr)
CN (1) CN1197554C (fr)
AR (1) AR025609A1 (fr)
AT (1) ATE285783T1 (fr)
AU (1) AU769016B2 (fr)
BR (1) BRPI0013940B1 (fr)
CA (1) CA2383036C (fr)
CO (1) CO5210857A1 (fr)
CZ (1) CZ301844B6 (fr)
DE (1) DE60017156T2 (fr)
EG (1) EG24225A (fr)
ES (1) ES2233444T3 (fr)
GC (1) GC0000259A (fr)
HK (1) HK1049798B (fr)
HR (1) HRP20020206B1 (fr)
HU (1) HU229037B1 (fr)
IL (2) IL148570A0 (fr)
JO (1) JO2300B1 (fr)
MA (1) MA26817A1 (fr)
ME (1) ME00675B (fr)
MX (1) MXPA02002662A (fr)
MY (1) MY127430A (fr)
NO (1) NO328889B1 (fr)
NZ (1) NZ517396A (fr)
PE (1) PE20010661A1 (fr)
PL (1) PL199869B1 (fr)
PT (1) PT1216048E (fr)
RS (1) RS50373B (fr)
RU (1) RU2248218C2 (fr)
SI (1) SI1216048T1 (fr)
TR (1) TR200200605T2 (fr)
WO (1) WO2001019378A2 (fr)
ZA (1) ZA200201249B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
CZ302087B6 (cs) 2000-07-28 2010-10-06 F. Hoffmann-La Roche Ag Farmaceutický prípravek obsahující orlistat spolu se sekvestrantem žlucových kyselin pro použití pro lécení a prevenci obezity
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
NZ542176A (en) * 2003-03-04 2007-12-21 Nostrum Pharmaceuticals Inc Control release formulation containing a hydrophobic material as the sustained release agent
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
EP1806149A4 (fr) * 2004-10-25 2012-12-05 Japan Tobacco Inc Préparation médicinale solide améliorée en termes de solubilité et de stabilité et procédé servant à produire celle-ci
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
EP1808163A1 (fr) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Formes galéniques solides comprimées avec des principes actifs de faible solubilité et leur procédé de fabrication
CA2626234A1 (fr) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Formes de dosage solides comprimees comprenant des medicaments de faible solubilite et procede servant a les fabriquer
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
KR100903504B1 (ko) * 2007-05-18 2009-06-17 강태용 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
CA2697150A1 (fr) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Procedes et compositions pour controler la biodisponibilite de medicaments faiblement solubles
PL2036575T3 (pl) * 2007-09-12 2011-02-28 Mader S R L Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
EP2486805A1 (fr) * 2011-02-11 2012-08-15 Puratos N.V. Émulsion à fouettement à température ambiante
PH12013501815A1 (en) * 2011-04-14 2013-10-14 J Oil Mills Inc Palm-based fractionated oil and fat, and oil and fat composition and food product containing the same
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
GB2501535A (en) 2012-04-26 2013-10-30 Sony Corp Chrominance Processing in High Efficiency Video Codecs
JP6341910B2 (ja) * 2012-05-31 2018-06-13 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンの経膣送達用製剤およびその送達方法
US9980934B2 (en) 2013-10-28 2018-05-29 Nestec S.A. Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (fr) * 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
FR2710264B1 (fr) * 1993-09-21 1995-12-08 Rocher Yves Biolog Vegetale Utilisation pour le traitement des peaux mixtes d'une quantité efficace de substances actives.
WO1998024607A1 (fr) * 1996-12-04 1998-06-11 Pincott James S Procede et dispositif servant a obtenir de la poudre de caoutchouc a partir de pneus de rebut
RU2201272C2 (ru) 1997-02-05 2003-03-27 Ф.Хоффманн-Ля Рош Аг Применение ингибиторов желудочно-кишечной липазы
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
PT1105123E (pt) * 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
CA2340056C (fr) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comportant des inhibiteurs de lipase
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas

Also Published As

Publication number Publication date
RS50373B (sr) 2009-11-10
EP1216048A2 (fr) 2002-06-26
AU7517700A (en) 2001-04-17
HU229037B1 (en) 2013-07-29
IL148570A (en) 2007-03-08
MEP90908A (en) 2011-12-20
DE60017156T2 (de) 2006-01-05
BR0013940A (pt) 2002-05-14
SI1216048T1 (en) 2005-06-30
MY127430A (en) 2006-11-30
CO5210857A1 (es) 2002-10-30
KR20020060177A (ko) 2002-07-16
JP4217017B2 (ja) 2009-01-28
BRPI0013940B1 (pt) 2016-06-21
ATE285783T1 (de) 2005-01-15
NO328889B1 (no) 2010-06-07
WO2001019378A3 (fr) 2001-05-10
ZA200201249B (en) 2003-07-30
EG24225A (en) 2008-11-10
CA2383036A1 (fr) 2001-03-22
HUP0202762A2 (hu) 2003-01-28
HRP20020206A2 (en) 2004-04-30
HRP20020206B1 (en) 2011-02-28
EP1216048B1 (fr) 2004-12-29
JP2003509373A (ja) 2003-03-11
TR200200605T2 (tr) 2002-08-21
RU2002107450A (ru) 2004-01-10
HUP0202762A3 (en) 2005-04-28
ME00675B (fr) 2011-12-20
WO2001019378A2 (fr) 2001-03-22
CN1373659A (zh) 2002-10-09
NZ517396A (en) 2003-10-31
HK1049798A1 (en) 2003-05-30
CZ20021277A3 (cs) 2003-04-16
CN1197554C (zh) 2005-04-20
CZ301844B6 (cs) 2010-07-07
PE20010661A1 (es) 2001-06-25
ES2233444T3 (es) 2005-06-16
RU2248218C2 (ru) 2005-03-20
PL199869B1 (pl) 2008-11-28
HK1049798B (zh) 2005-08-05
AR025609A1 (es) 2002-12-04
PL356154A1 (en) 2004-06-14
IL148570A0 (en) 2002-09-12
DE60017156D1 (de) 2005-02-03
NO20021205D0 (no) 2002-03-12
KR100523879B1 (ko) 2005-10-26
US6703369B1 (en) 2004-03-09
YU13602A (sh) 2006-01-16
MXPA02002662A (es) 2002-07-30
PT1216048E (pt) 2005-04-29
NO20021205L (no) 2002-03-12
JO2300B1 (en) 2005-09-12
AU769016B2 (en) 2004-01-15
CA2383036C (fr) 2006-01-10
GC0000259A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
MA26817A1 (fr) Formulations de lipides solides
ID23299A (id) Formulasi-formulasi farmasi
DK1001813T3 (da) Farmaceutiske formuleringer indeholdende voriconazol
DK0965343T3 (da) Ziprasidonformuleringer
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
NO20004240L (no) Formuleringer
ID24654A (id) Formulasi farmasi omeprazola
ATE224703T1 (de) Brauseformulierungen
MA24473A1 (fr) Formulations
PT1130966E (pt) Formulacoes antiparasitarias
DK1168916T3 (da) Landbrugskemikalieformuleringer
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
NO20015670L (no) Forbedrede farmasöytiske formuleringer
PT1237408E (pt) Formulacoes para derramar
DK1466615T3 (da) Farmaceutisk præparat
IS6398A (is) Lyfjablöndur
PT868911E (pt) Formulacoes de rapamicina para administracao oral
ID30032A (id) Formulasi farmasi
ID16781A (id) Formulasi-formulasi farmasi
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200000330A (et) Farmatseutilised kompositsioonid
DE60017700D1 (de) Bildgebungsverfahren
SE9803952D0 (sv) Pharmaceutical formulation
DK1237551T3 (da) Farmaceutiske formuleringer indeholdende zolmitriptan